Vivo Capital’s Viridian Therapeutics VRDN Stock Holding History

Vivo Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-166,288	Closed	-$3.25M	–	52
2026 Q1	$3.25M	Sell	166,288 -816,288	-83%	-$24.2M	0.27%	41
2025 Q4	$30.6M	Hold	982,576	–	–	1.98%	18
2025 Q3	$21.2M	Hold	982,576	–	–	1.71%	19
2025 Q2	$13.7M	Hold	982,576	–	–	1.41%	12
2025 Q1	$13.2M	Hold	982,576	–	–	1.75%	9
2024 Q4	$18.8M	Sell	982,576 -695,631	-41%	-$15.1M	2.11%	9
2024 Q3	$38.2M	Hold	1,678,207	–	–	3.16%	9
2024 Q2	$21.8M	Hold	1,678,207	–	–	2.02%	10
2024 Q1	$29.4M	Hold	1,678,207	–	–	2.31%	11
2023 Q4	$36.6M	Hold	1,678,207	–	–	2.99%	9
2023 Q3	$25.7M	Hold	1,678,207	–	–	2.82%	11
2023 Q2	$39.9M	Hold	1,678,207	–	–	2.76%	8
2023 Q1	$42.7M	Hold	1,678,207	–	–	2.96%	6
2022 Q4	$49M	Buy	1,678,207 +18,188	+1%	+$419K	5.64%	3
2022 Q3	$34M	Buy	1,660,019 +360,019	+28%	+$6.47M	3.76%	10
2022 Q2	$15M	Hold	1,300,000	–	–	1.51%	16
2022 Q1	$24M	Hold	1,300,000	–	–	1.66%	12
2021 Q4	$25.7M	Hold	1,300,000	–	–	1.55%	15
2021 Q3	$21.4M	Buy	+1,300,000	New	+$19.1M	0.96%	23

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital's VRDN Position: Q2 2026 in Review

Vivo Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 166,288 shares — an estimated $3.25M sold.

Vivo Capital first reported a position in VRDN in Q3 2021 and held it in 19 quarters. The position peaked at $49M in Q4 2022. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Vivo Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Vivo Capital sold 166,288 Viridian Therapeutics shares in Q2 2026, an estimated $3.25M.
Vivo Capital first reported a position in Viridian Therapeutics in Q3 2021 and held it in 19 quarters.
Vivo Capital's Viridian Therapeutics position peaked at $49M in Q4 2022.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.